Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Biosimilars Deals 2023
Biosimilars Deals 2024
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Trade Marks

Pearce IP BioBlast™: w/e 03 Apr 2020

by | Apr 6, 2020

Significant biosimilar activities this week include

30 Mar 20 | Biocad announced it had received registration certificates from Bosnia and Herzegovina for Acellbia® (rituximab) and Herticad® (trastuzumab), with a launch expected in 2020.

30 Mar 20 | In response to CoVid-19, Genentech announced it would extend physician payment terms for Lucentis® (ranibizumab) purchases to 120 days, up from the previous 60 day term. These new terms will be implemented from 01 April, 2020, as well as retroactively for Lucentis® purchased on or after March 1, 2020.

01 Apr 20 | A new study reported that Truxima® (rituximab) is comparable to the originator in terms of efficacy and safety in the treatment of multiple sclerosis. Rituximab is not currently indicated for multiple sclerosis but it is used off-label in some cases and is under investigation as a potential treatment.

02 Apr 20 | Pfizer announced EC approval of Ruxience® (rituximab) for the treatment of non-hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis, and pemphigus vulgaris.

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News